Stopping GLP-1 & Tirzepatide Therapy May Reverse Major Health Benefits, Warns New Review
A newly published review in Nature Reviews Endocrinology highlights a growing concern in obesity and diabetes care: many patients are discontinuing GLP-1 receptor agonists (GLP-1RAs) and tirzepatide therapy early, potentially leading to weight regain, worsening diabetes control, and increased cardiovascular risk.
The article, titled “Causes and consequences of discontinuation of GLP1RAs or tirzepatide”, was published on May 21, 2026.
It reviews real-world evidence regarding the increasing use — and frequent discontinuation — of modern anti-obesity and anti-diabetes medications such as semaglutide and tirzepatide.
Key Findings
Researchers report that GLP-1RA medications and tirzepatide have become central treatments for:
- Obesity
- Type 2 diabetes mellitus
- Cardiovascular risk reduction
- Kidney disease prevention
These drugs are known for producing substantial:
- Weight loss
- HbA1c reduction
- Improvement in metabolic syndrome
- Cardiovascular and renal protection
However, the review notes that many patients discontinue therapy within the first year.
Why Patients Stop Treatment
The most common causes of discontinuation include:
- Gastrointestinal side effects (nausea, vomiting, bloating, diarrhea)
- High medication cost
- Unsatisfactory weight-loss expectations
- Fear of rare adverse effects
- Difficulty maintaining long-term therapy adherence
What Happens After Stopping?
According to the review, discontinuation is commonly followed by:
- Significant weight regain
- Return of poor glycemic control
- Worsening blood pressure and lipid profile
- Loss of previous cardiometabolic improvements
The authors also warn that repeated cycles of:
“starting, stopping, and restarting”
these medications may cause fluctuations in body weight and HbA1c, both of which are independently associated with higher cardiovascular and microvascular complication risk.
Possible Cardiovascular Concerns
An important concern raised by the review is the potential loss of:
- Anti-atherosclerotic effects
- Plaque stabilization benefits
after stopping GLP-1-based therapies. Researchers suggest this could theoretically increase cardiovascular risk, although long-term outcome data remain limited.
Clinical Implications
The review emphasizes that obesity should be treated as a chronic disease requiring long-term management, similar to hypertension or diabetes.
Experts recommend:
- Better patient counseling before therapy initiation
- Gradual dose escalation to reduce GI side effects
- Long-term affordability strategies
- Lifestyle therapy continuation even after medication withdrawal
- Research into maintenance strategies after stopping therapy
Important Takeaway for Patients
Doctors advise that patients should not abruptly stop GLP-1 or tirzepatide medications without medical supervision. Treatment decisions should always be individualized based on:
- BMI
- Metabolic disease status
- Side effects
- Cost considerations
- Long-term weight maintenance goals
Article Reference